![]()
|
|
||||||||
J. Biol. Chem., Vol. 280, Issue 38, 32625-32633, September 23, 2005
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
From the Thrombosis and Haemostasis Laboratory, Department of Hematology, University Medical Center Utrecht, and the Institute for Biomembranes, Utrecht University, HP G03.647, Heidelberglaan 100, Utrecht 3584 CX, the Netherlands
In insulin-responsive tissues, insulin is a potent activator of protein kinase B (PKB)-mediated glucose uptake through the facilitative glucose transporter GLUT4. In platelets, glucose uptake is mediated through GLUT3, which is present in plasma (15%) and intracellular
-granule (85%) membranes. Here we report the PKB-mediated glucose uptake by platelets by agents that do (thrombin) or do not (insulin) induce
-granule translocation to the plasma membrane. Both thrombin and insulin activate PKB and induce glucose uptake albeit with different kinetics. Inhibition of PKB by the pharmacological inhibitor ML-9 decreases thrombin-induced
-granule release and thrombin- and insulin-induced glucose uptake. At low glucose (0.1 mM), both agents stimulate glucose uptake by lowering the Km for glucose (thrombin and insulin) and increasing Vmax (thrombin). At high glucose (5 mM), stimulation of glucose uptake by insulin disappears, and insulin becomes an inhibitor of thrombin-induced glucose uptake via mechanisms independent of PKB. We conclude that in platelets glucose transport through GLUT3 is regulated by changes in surface expression and affinity modulation, which are both under control of PKB.
Received for publication, July 5, 2005
* This work was supported in part by the Dutch Diabetes Research Foundation (Grant 1999.046) and the Fonds voor het Hart. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
1 Supported by the Dutch Thrombosis Foundation. To whom correspondence should be addressed. Tel.: 31-30-250-6512; Fax: 31-30-251-1893; E-mail: j.w.n.akkerman{at}azu.nl.
![]()
CiteULike
Complore
Connotea
Del.icio.us
Digg
Reddit
Technorati What's this?
This article has been cited by other articles:
![]() |
I. A. Simpson, D. Dwyer, D. Malide, K. H. Moley, A. Travis, and S. J. Vannucci The facilitative glucose transporter GLUT3: 20 years of distinction Am J Physiol Endocrinol Metab, August 1, 2008; 295(2): E242 - E253. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. M.W. Verheul, M. P.J. Lolkema, D. Z. Qian, Y. H.A. Hilkes, E. Liapi, J.-W. N. Akkerman, R. Pili, and E. E. Voest Platelets Take Up the Monoclonal Antibody Bevacizumab Clin. Cancer Res., September 15, 2007; 13(18): 5341 - 5347. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. A. Ferreira, A. I.M. Mocking, M. A.H. Feijge, G. Gorter, T. W. van Haeften, J. W.M. Heemskerk, and J.-W. N. Akkerman Platelet Inhibition by Insulin Is Absent in Type 2 Diabetes Mellitus Arterioscler. Thromb. Vasc. Biol., February 1, 2006; 26(2): 417 - 422. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| All ASBMB Journals | Molecular and Cellular Proteomics |
| Journal of Lipid Research | ASBMB Today |